Client News

Abivax Publishes 2025 Financial Calendar

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Formycon Receives EU Approval for FYB203 (Aflibercept), a Biosimilar to Eylea®, Under the Brand Names AHZANTIVE® and Baiama®

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

Formycon and Fresenius Kabi Announce MHRA Approval for FYB202/Otulfi® (Ustekinumab), a Biosimilar to Stelara®

Heidelberg Pharma AG Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma

Teva Becomes Strategic Commercialization Partner for Formycon’s Biosimilar Candidate FYB203 (Eylea® / aflibercept) in Major Parts of Europe and Israel